Abstract
Capsaicin appears to be effective for osteoarthritis pain but it is uncertain whether the effect has a dose response, is consistent across joints, or changes over time. Methods: Randomized controlled trials of topical capsaicin use in OA were identified from PubMed, EMBASE, and ISI Web of Knowledge. Effect on pain scores, patient global evaluation of treatment effectiveness and application site burning were assessed by standardised mean differences (SMD), using RevMan. Results: Five double–blind randomized controlled trials and one case–crossover trial of topical capsaicin use were identified. Formulations ranged from 0.025 to 0.075 %, and trial durations from 4 to 12 weeks. Trials assessed OA of the knee (n = 3), hand (n = 1), and a mix of joints (n = 2). Capsaicin treatment efficacy (vs. placebo) for change in VAS pain score was moderate, at 0.44 (95 % CI 0.25–0.62) over 4 weeks of treatment. There was no heterogeneity between studies, indicating no between-study differences, including effect of OA site or treatment concentration. Two studies reported treatment beyond 4 weeks, with divergent results. One study reported an effect size of −9 mm after 12 weeks, and maximal between-group differences at 4 weeks. A second study reported that between-group differences increased over time, up to 20 weeks. Capsaicin was reported as being safe and well–tolerated, with no systemic toxicity. Mild application site burning affected 35–100 % of capsaicin–treated patients with a risk ratio of 4.22 (95 % CI 3.25–5.48, n = 5 trials); incidence peaked in week 1, with incidence rates declining over time. Conclusions: Topical capsaicin treatment four times daily is moderately effective in reducing pain intensity up to 20 weeks regardless of site of application and dose in patients with at least moderate pain and clinical or radiologically defined OA, and is well tolerated.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Altman RD, Aven A, Holmburg CE, Pfeifer LM, Sack M, Young GT (1994) Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum 23(6 (Suppl 3)):S25–33
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 343(21):1520–1528. doi:10.1056/nejm200011233432103
Baron R (2000) Capsaicin and nociception: from basic mechanisms to novel drugs. Lancet 356(9232):785–787. doi:10.1016/s0140-6736(00)02649-0
Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102. doi:10.1056/NEJMoa050493
Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL (2011) Stroke risk and NSAIDs: an Australian population-based study. Med J Aust 195(9):525–529
Cohen J (1988) Statistical power analysis for behavioral sciences, 2nd edn. Lawrence Erlbaum Associates Incorporated, New Jersey
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389(6653):816–824. doi:10.1038/39807
Dieppe PA, Lohmander LS (2005) Pathogenesis and management of pain in osteoarthritis. Lancet 365(9463):965–973. doi:10.1016/s0140-6736(05)71086-2
Deal CL (1994) The use of topical capsaicin in managing arthritis pain: a clinician’s perspective. Semin Arthritis Rheum 23(6 Suppl 3):48–52
Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F (1991) Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 13(3):383–395
Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR (2004) Treatment options in knee osteoarthritis: the patient’s perspective. Arch Intern Med 164(12):1299–1304. doi:10.1001/archinte.164.12.1299
Fusco BM, Giacovazzo M (1997) Peppers and pain. The promise of capsaicin. Drugs 53(6):909–914
Fortier LA, Nixon AJ (1997) Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations. J Rheumatol 24(3):524–530
Jancso G, Kiraly E, Jancso-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 270(5639):741–743
Kidd BL, Morris VH, Urban L (1996) Pathophysiology of joint pain. Ann Rheum Dis 55(5):276–283
Kenins P (1982) Responses of single nerve fibres to capsaicin applied to the skin. Neurosci Lett 29(1):83–88
Kosuwon W, Sirichatiwapee W, Wisanuyotin T, Jeeravipoolvarn P, Laupattarakasem W (2010) Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thai 93(10):1188–1195
McCleane G (2000) The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain 4(4):355–360. doi:10.1053/eujp.2000.0200
McCarthy GM, McCarty DJ (1992) Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 19(4):604–607
Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 81(1–2):135–145
Pernow B (1983) Substance P. Pharmacol Rev 35(2):85–141
Schaible HG, Grubb BD (1993) Afferent and spinal mechanisms of joint pain. Pain 55(1):5–54
Schnitzer TJ, Pelletier JP, Haselwood DM, Ellison WT, Ervin JE, Gordon RD, Lisse JR, Archambault WT, Sampson AR, Fezatte HB, Phillips SB, Bernstein JE (2012) Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension. J Rheumatol 39(3):610–620. doi:10.3899/jrheum.110192
Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51(2):159–212
Szallasi A, Blumberg PM (2007) Complex regulation of TRPV1 by vanilloids. TRP ion channel function in sensory transduction and cellular signaling cascades. CRC Press, Boca Raton
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080. doi:10.1056/NEJMoa050405
Theriault E, Otsuka M, Jessell T (1979) Capsaicin-evoked release of substance P from primary sensory neurons. Brain Res 170(1):209–213
Valdes AM, De Wilde G, Doherty SA, Lories RJ, Vaughn FL, Laslett LL, Maciewicz RA, Soni A, Hart DJ, Zhang W, Muir KR, Dennison EM, Wheeler M, Leaverton P, Cooper C, Spector TD, Cicuttini FM, Chapman V, Jones G, Arden NK, Doherty M (2011) The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis 70(9):1556–1561. doi:10.1136/ard.2010.148122
Wood JN, Winter J, James IF, Rang HP, Yeats J, Bevan S (1988) Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J Neurosci 8(9):3208–3220
Wojtys EM, Beaman DN, Glover RA, Janda D (1990) Innervation of the human knee joint by substance-P fibers. Arthroscopy 6(4):254–263
Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499. doi:10.1016/j.joca.2010.01.013
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Basel
About this chapter
Cite this chapter
Laslett, L.L., Jones, G. (2014). Capsaicin for Osteoarthritis Pain. In: Abdel-Salam, O. (eds) Capsaicin as a Therapeutic Molecule. Progress in Drug Research, vol 68. Springer, Basel. https://doi.org/10.1007/978-3-0348-0828-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-0348-0828-6_11
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0348-0827-9
Online ISBN: 978-3-0348-0828-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)